Mineralys prices upsized $250M public offering at $25.50/share

Mineralys Therapeutics, Inc.

9,803,921 shares at $25.50/share; total gross proceeds ~$250M.
Net proceeds ~$234.7M (~$269.9M if underwriters' option exercised).
Proceeds to fund lorundrostat clinical development, R&D, manufacturing, and pre-commercialization.
Underwriters: BofA, Evercore, Goldman, Stifel, Wells Fargo; closing expected Sept 4, 2025.
Upsized offering reflects strong demand; underwriters have 30-day option for 1.47M additional shares.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.